

U.S.S.N. 09/864,078

Transmittal of Information Disclosure Statement dated June 23, 2003



1623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sommadossi *et al.*

Serial No.: 09/864,078

Group Art Unit : 1623

Filed: May 23, 2001

Examiner: Howard Owens

Title: Methods and Compositions for Treating Hepatitis C Virus

RECEIVED

JUL 07 2003

TECH CENTER 1600/2000

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. In addition, Applicants bring to the Examiner's attention the following related U.S. applications currently pending (U.S.S.N.s 60/392,351; 60/392,350; 60/426,675; 60/432,766; 60/436,150; and 09/863,816) which are assigned to Idenix Pharmaceuticals, Inc., which is the same assignee as the above-identified patent application. Applicants also enclose a copy of the International Search Report for the corresponding International Application No. PCT/US01/16671 for the Examiner's review, as well as the International Search Report for the related case, International Application No. PCT/US01/16687. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,



Sherry M. Knowles, Esq.
Reg. No. 33,052

KING & SPALDING LLP
191 Peachtree Street
Atlanta, GA 30303
404-572-3451 (Telephone)
404-572-5145 (Facsimile)



CERTIFICATE OF MAILING UNDER 37 CFR § 1.8 (a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450.

A handwritten signature in black ink, appearing to read "Hoang M. Vo". Below the signature, the text "Reg. No. 47,158" is printed.

Date: June 23, 2003

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO
**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				<i>Complete if Known</i>	
				Application Number	09/864,078
				Filing Date	23 May 2001
				First Named Inventor	Sommadossi, J.-P. et al.
				Group Art Unit	1623
Sheet 1 of 2				Attorney Docket Number	06171.105022

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A	6,395,716		Novirio Pharmaceuticals Limited	28 May 2002
	B	6,444,652		Novirio Pharmaceuticals Limited	03 September 2002
	C	6,340,690		Bio-Chem Pharma, Inc.	02 January 2002


FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY
		Office ³	Number	Kind Code ² (if known)		
	D	WO	00/09531		Novirio Pharmaceuticals Limited	24 February 2000
	E	WO	01/60315	A3	Shire Biochem Inc.	23 August 2001
	F	WO	01/90121		Novirio Pharmaceuticals Limited	29 November 2001
	G	WO	01/91737		Novirio Pharmaceuticals Limited	29 May 2001
	H	WO	01/92282		Novirio Pharmaceuticals Limited	26 May 2001
	I	WO	01/96353		Novirio Pharmaceuticals Limited	20 December 2001
	J	WO	02/057287	A2	Merck & Co. Inc.	25 July 2002
	K	WO	02/057425	A2	Merck & Co. Inc.	25 July 2002

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Submitted for Form 1449/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 2 of 2

		<i>Complete if Known</i>	
Application Number		09/864,078	
Filing Date		23 May 2001	
First Named Inventor		Sommadossi, J.-P. et al.	
Group Art Unit		1623	
Attorney Docket Number		06171.105022	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number				
L	WO	02/070533		A3	Pharmasset LTD.	12 September 2002	
M	WO	02/094289		A1	F. Hoffmann-La Roche AG	28 November 2002	
N	WO	02/100415		A2	F. Hoffmann-La Roche AG	19 December 2002	
O	WO	02/18404		A2	F. Hoffmann-La Roche AG	07 March 2002	
P	WO	02/32920		A2	Pharmasset LTD.	25 April 2002	
Q	WO	03/026675			Idenix Pharmaceuticals Inc.	03 April 2003	
R	WO	03/26589			Idenix Pharmaceuticals Inc.	03 April 2003	
S	WO	02/48165		A2	Pharmasset LTD.	17 December 2001	
T	WO	01/79246			Pharmasset LTD.	13 April 2001	
U	WO	01/32153			Bio-Chem Pharma, Inc.	03 November 2000	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
V		FRANCESCO et al., Antiviral Research 58 (2003) 1-16	
W		Oral Session V : Hepatitis C Virus, Flaviviruses	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.